Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an announcement.
Rhythm Biosciences Ltd has entered a strategic collaboration with Memorial Sloan Kettering Cancer Center to support clinical trials focused on breast and prostate cancer risk. This partnership aims to advance the use of polygenic risk scores in cancer risk assessment, potentially impacting the company’s operations by enhancing its industry positioning in precision cancer prevention. The collaboration will involve processing at least 300 participants and underscores Rhythm’s commitment to leveraging genomic risk prediction for earlier detection and informed decision-making.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes by detecting cancers at the earliest possible stage. Rhythm Biosciences collaborates with global partners to commercialize and distribute its diagnostic solutions, including the ColoSTAT Test-Kit for colorectal cancer and the geneType platform for genetic risk assessment.
Average Trading Volume: 322,668
Technical Sentiment Signal: Sell
Current Market Cap: A$15.39M
For a thorough assessment of RHY stock, go to TipRanks’ Stock Analysis page.